Chinese Journal of Cancer Research

, Volume 19, Issue 3, pp 165–170 | Cite as

Risk factors for fatal recurrence of liver transplant recipients with hepatocellular carcinoma in the first year

  • Zou Wei-long  (邹卫龙)
  • Zang Yun-jin  (藏运金)
  • Chen Xin-guo  (陈新国)
  • Shen Zhong-yang  (沈中阳)



To investigate the clinicopathological risk factors for fatal recurrence of hepatocellular carcinoma (HCC) in orthotopic liver transplant recipients in the first year.


From April 2002 to October 2005, 303 recipients who received orthotopic liver transplantation for HCC were reviewed. Of These patients, those who demonstrated diffuse intra-hepatic or multiple systemic recurrent lesions and died within 1 y after surgery were investigated (fatal recurrence group, 48 cases). The remaining patients were designated as the control group, and the two groups were compared for clinicopathologic risk factors by logistic regression analysis.


Among the 303 patients reviewed, 48 patients were enrolled in the fatal recurrence group (15.84%). Multivariate analysis between the fatal recurrence group and control group showed that the presence of vascular invasion, tumor size greater than 6.5 cm, and pre-operative serum alpha-fetoprotein (AFP) level greater than 1000 μg/L were the risk factors in the fatal recurrence group. 85.71% of the patients who had all the three risk factors, 37.84% of those who had two risk factors, 13.64% of those who had one risk factors, and 6.71% of those who had none risk factors died because of recurrence within 1 y after transplantation.


Three distinct risk factors attributed to fatal recurrence of liver transplant recipients for HCC are vascular invasion, tumor size ≥6.5 cm, and pre-operative serum AFP level ≥1000 μg/L. The high risk HCC patients with two or more risk factors should not to be the candidates for liver transplantation.

Key words

Hepatocellular carcinoma Liver transplantation Recurrence Mortality 

CLC number



  1. [1]
    Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma [J]. Lancet 2003; 362:1907–1917.PubMedCrossRefGoogle Scholar
  2. [2]
    Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma [J]. Semin Liver Dis 2005; 25:181–200.PubMedCrossRefGoogle Scholar
  3. [3]
    Zavaglia C, De Carlis L, Alberti AB, et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma [J]. Am J Gastroenterol 2005; 100:2708–2716.PubMedCrossRefGoogle Scholar
  4. [4]
    Merli M, Nicolini G, Gentili F, et al. Predictive factors of outcome after liver transplantation in patients with cirrhosis and hepatocellular carcinoma [J]. Transplant Proc 2005; 37:2535–2540.PubMedCrossRefGoogle Scholar
  5. [5]
    Zhou J, Fan J, Wu ZQ, et al. Liver transplantation for patients with hepatocellular carcinoma at the Liver Center Institute of Fudan University, China [J]. Chin Med J 2005; 118:654–659.PubMedGoogle Scholar
  6. [6]
    Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma [J]. Semin Liver Dis 1999; 19:311–322.PubMedCrossRefGoogle Scholar
  7. [7]
    Shah SA, Tan JC, McGilvray ID, et al. Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma [J]. Transplantation 2006; 81:1633–1639.PubMedCrossRefGoogle Scholar
  8. [8]
    Kim BW, Kim YB, Wang HJ, et al. Risk factors for immediate post-operative fatal recurrence after curative resection of hepatocellular carcinoma [J]. World J Gastroenterol 2006; 12:99–104.PubMedGoogle Scholar
  9. [9]
    Karakayali H, Moray G, Sozen H, et al. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma [J]. Transplant Proc 2006; 38:575–578.PubMedCrossRefGoogle Scholar
  10. [10]
    Wang DC, Zhang TL, Song SB, et al. A report of 28 cases of 3-year follow-up after liver transplantation for advanced hepatocellular carcinoma [J]. World J Gastroenterol 2004; 10:2134–2135.PubMedGoogle Scholar
  11. [11]
    Ercolani G, Grazi GL, Ravaioli M, et al. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence [J]. Ann Surg 2003; 237:536–543.PubMedCrossRefGoogle Scholar
  12. [12]
    Yu AS, Keeffe EB. Management of hepatocellular carcinoma [J]. Rev Gastroenterol Disord 2003; 3:8–24.PubMedGoogle Scholar
  13. [13]
    Befeler AS, Hayashi PH, Di Bisceglie AM. Liver transplantation for hepatocellular carcinoma [J]. Gastroenterology 2005; 128:1752–1764.PubMedCrossRefGoogle Scholar
  14. [14]
    Sotiropoulos GC, Malagó M, Molmenti E, et al. Liver transplantation for hepatocellular carcinoma in cirrhosis: is clinical tumor classification before transplantation realistic [J]? Transplantation 2005; 79:483–487.PubMedCrossRefGoogle Scholar
  15. [15]
    Zhou LX, Yan LN. Prognostic factors of hepatocellular carcinoma after liver transplantation [J]. Chin J Cancer (in Chin) 2006; 25:736–739.Google Scholar
  16. [16]
    Jonas S, Bechstein WO, Steinmüller T, et al. Vascular invasion and histologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis [J]. Hepatology 2001; 33:1080–1086.PubMedCrossRefGoogle Scholar
  17. [17]
    Durand F, Belghiti J. Liver transplantation for hepatocellular carcinoma: should we push the limits [J]? Liver Transpl 2003; 9:697–699.PubMedCrossRefGoogle Scholar
  18. [18]
    Marsh JW, Dvorchik I, Bonham CA, et al. Is the pathologic TNM staging system for patients with hepatoma predictive of outcome [J]? Cancer 2000; 88:538–543.PubMedCrossRefGoogle Scholar
  19. [19]
    Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma [J]. Liver Transpl 2005; 11:1086–1092.PubMedCrossRefGoogle Scholar
  20. [20]
    Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with Milan criteria and the Pittsburgh modified TNM criteria [J]. Liver Transpl 2002; 8:765–774.PubMedCrossRefGoogle Scholar
  21. [21]
    Fernández JA, Robles R, Marin C, et al. Can we expand the indications for liver transplantation among hepatocellular carcinoma patients with increased tumor size [J]? Transplant Proc 2003; 35:1818–1820.PubMedCrossRefGoogle Scholar
  22. [22]
    Cillo U, Nasvaglia F, Vitale A, et al. Clinical significance of alpha-fetoprotein mRNA in blood of patients with hepatocellular carcinoma [J]. Clin Chim Acta 2004; 347:129–138.PubMedCrossRefGoogle Scholar
  23. [23]
    Cillo U, Vitale A, Navaglia F, et al. Role of blood AFP mRNA and tumor grade in the preoperative prognostic evaluation of patients with hepatocellular carcinoma [J]. World J Gastroenterol 2005; 11:6920–6925.PubMedGoogle Scholar
  24. [24]
    Gross-Goupil M, Saffroy R, Azoulay D, et al. Real-time quantification of AFP mRNA to assess hematogenous dissemination after transarterial chemoembolization of hepatocellular carcinoma [J]. Ann Surg 2003; 238:241–248.PubMedGoogle Scholar
  25. [25]
    Ijichi M, Takayama T, Matsumura M, et al. alpha-Fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: a prospective study [J]. Hepatology 2002; 35:853–860.PubMedCrossRefGoogle Scholar

Copyright information

© Chinese Anti-Cancer Association 2007

Authors and Affiliations

  • Zou Wei-long  (邹卫龙)
    • 1
  • Zang Yun-jin  (藏运金)
    • 1
  • Chen Xin-guo  (陈新国)
    • 1
  • Shen Zhong-yang  (沈中阳)
    • 1
  1. 1.Institute of Transplantationthe General Hospital of Chinese People’s Armed Police ForcesBeijingChina

Personalised recommendations